1. Home
  2. FICO vs BBIO Comparison

FICO vs BBIO Comparison

Compare FICO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

N/A

Current Price

$671.96

Market Cap

15.3B

ML Signal

N/A

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$78.15

Market Cap

13.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FICO
BBIO
Founded
1956
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3B
13.3B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
FICO
BBIO
Price
$671.96
$78.15
Analyst Decision
Buy
Buy
Analyst Count
21
22
Target Price
★ $821.37
$107.00
AVG Volume (30 Days)
700.9K
★ 2.7M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.85
N/A
EPS
★ 36.32
N/A
Revenue
★ $1,032,475,000.00
$502,076,000.00
Revenue This Year
$2.20
$118.56
Revenue Next Year
$6.47
$51.71
P/E Ratio
$18.62
★ N/A
Revenue Growth
N/A
★ 126.26
52 Week Low
$595.19
$62.50
52 Week High
$1,858.91
$93.42

Technical Indicators

Market Signals
Indicator
FICO
BBIO
Relative Strength Index (RSI) 38.04 60.89
Support Level $662.30 $63.62
Resistance Level $760.65 $85.42
Average True Range (ATR) 33.72 2.96
MACD 1.41 0.13
Stochastic Oscillator 25.17 60.59

Price Performance

Historical Comparison
FICO
BBIO

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac is a leading applied analytics company. It is primarily known for its FICO credit scores, a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: